Sign inGet started

Day Lucy

Insider CIK 1914510 · ANTX Chief Financial Officer

Track record PRO

XXXX$█.██M██+██%
XXXX$█.██M██+██%
XXXX$█.██M██+██%
Track record
See how this insider's past purchases performed 30 and 90 days later, and a conviction score on each buy.
Upgrade to Pro · $99/yearAlready Pro? Log in

Trades across companies

TickerCodeTradeFiledSharesPriceValueOwned after
ANTX AN2 Therapeutics, Inc. D To issuer deriv2026-03-192026-03-2382,300— $00SEC↗
ANTX AN2 Therapeutics, Inc. A Award deriv2026-03-192026-03-2373,665— $073,665SEC↗
ANTX AN2 Therapeutics, Inc. D To issuer deriv2026-03-192026-03-2373,665— $00SEC↗
ANTX AN2 Therapeutics, Inc. A Award deriv2026-03-192026-03-2366,000— $066,000SEC↗
ANTX AN2 Therapeutics, Inc. D To issuer deriv2026-03-192026-03-2366,000— $00SEC↗
ANTX AN2 Therapeutics, Inc. A Award deriv2026-03-192026-03-2382,300— $082,300SEC↗
ANTX AN2 Therapeutics, Inc. A Award deriv2026-02-202026-02-2377,000— $077,000SEC↗
ANTX AN2 Therapeutics, Inc. A Award2026-02-202026-02-2338,000— $0118,363SEC↗
ANTX AN2 Therapeutics, Inc. S Sale2026-01-062026-01-075,512$1.01 $5.6K75,363SEC↗
ANTX AN2 Therapeutics, Inc. S Sale2026-01-052026-01-073,295$1.00 $3.3K80,875SEC↗
ANTX AN2 Therapeutics, Inc. A Award deriv2025-02-262025-02-2893,000— $093,000SEC↗
ANTX AN2 Therapeutics, Inc. A Award2025-02-262025-02-2846,500— $079,170SEC↗
ANTX AN2 Therapeutics, Inc. S Sale2025-01-032025-01-072,957$1.34 $4.0K32,670SEC↗
ANTX AN2 Therapeutics, Inc. A Award deriv2024-03-152024-03-1855,000— $055,000SEC↗
ANTX AN2 Therapeutics, Inc. A Award2024-03-152024-03-1827,500— $030,627SEC↗
ANTX AN2 Therapeutics, Inc. A Award2024-03-152024-03-2927,500— $030,627SEC↗
ANTX AN2 Therapeutics, Inc. A Award deriv2023-02-152023-02-1782,300— $082,300SEC↗
ANTX AN2 Therapeutics, Inc. A Award deriv2022-05-122022-05-1666,000— $066,000SEC↗